Clinical presentation of patients with lower limb spasticity undergoing routine treatment with botulinum toxin: baseline findings from an international observational study.
Alberto Esquenazi, Richard D Zorowitz, Stephen Ashford and 3 others
PMID 37794845WHAT IT FOUND
Ambulatory patients with lower limb spasticity face widespread difficulties with dressing, walking, and daily activities, alongside high rates of sensory, cognitive, and communication impairments.
Most prioritize locomotion goals, but complex comorbidities require comprehensive assessment before treatment.
Key findings
01Most patients had significant functional limitations, with over half reporting moderate difficulty putting on trousers and footwear, and most reporting at least moderate difficulty with outdoor ambulation and stairs.
02High prevalence of co-occurring impairments was observed, including distal motor impairment in 99.1% of those assessed, sensory impairment in nearly three-quarters, and communication impairment in a similar proportion.
03Active function goals, particularly locomotion, were selected by half of the patients as their primary treatment goal, while impairment-focused goals like pain were chosen less frequently.
STILL TO COME
How it was doneWhat they foundWhat it means for PTsWhat it means for OTsWhat it means for SLPs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The study only included ambulatory patients who were considered good candidates for botulinum toxin treatment, so findings do not apply to non-ambulatory patients or those with severe contractures. There was a large amount of missing data for the Neurological Impairment Scale, limiting the generalizability of the impairment findings. The study was descriptive and did not analyze treatment outcomes or effectiveness, so it cannot determine if the prioritized goals were actually achieved. Patients with progressive neurological conditions and cerebral palsy were excluded, restricting the applicability to acquired brain injury populations.
Declared interests
The study was conducted in compliance with International Society for Pharmacoepidemiology guidelines. The text does not explicitly state who funded the study, but it is an observational study of routine care involving a specific drug (abobotulinumtoxinA), which often implies industry sponsorship. No specific conflict of interest statements for individual authors are provided in the text.
The easy way to misread this
Do not interpret these baseline characteristics as evidence that botulinum toxin treatment resolves these impairments or achieves the selected goals. The study reports what patients presented with before treatment, not the outcomes of the intervention.